Akebia Therapeutics Announces September 2020 Investor Conference Schedule
CAMBRIDGE, Mass., Sept. 8, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will participate in the following virtual investor conferences in September.
Citi's 15th Annual BioPharma Conference John P. Butler, President and Chief Executive Officer, to participate in virtual one-on-one meetings on Wednesday, September 9.
H.C. Wainwright 22nd Annual Global Investment Conference Michel Dahan, Chief Operating Officer, and David Spellman, Chief Financial Officer, to participate in a virtual fireside chat on Monday, September 14, at 10:00 a.m. ET.
Morgan Stanley Virtual 18th Annual Global Healthcare Conference John P. Butler, President and Chief Executive Officer, to participate in a fireside chat on Tuesday, September 15, at 1:15 p.m. ET.
Cantor Virtual Global Healthcare Conference John P. Butler, President and Chief Executive Officer, to present on Wednesday, September 16, at 1:20 p.m. ET.
Where applicable, live webcasts of Akebia's presentations will be made available on the Investors section on the Company's website at https://ir.akebia.com.
About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact Kristen K. Sheppard, Esq. [email protected]
Pieper Veterinary, a Northeastern-based family of primary, specialty, and emergency care veterinary hospitals, is excited to announce they have partnered with Lebanon Veterinary Hospital in Lebanon CT. This partnership continues Pieper's strategy to...
NRx Pharmaceuticals, Inc. ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of...
Acadia Pharmaceuticals Inc. today announced that two oral presentations featuring DAYBUEtm (trofinetide) findings in Rett syndrome will be presented at the American Academy of Neurology (AAN) 2024 annual meeting, being held this week in Denver, CO....
DiaMedica Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today announced the first patient being dosed in DiaMedica's relaunch of its pivotal...
Jazz Pharmaceuticals plc today announced that it will report its 2024 first quarter financial results on Wednesday, May 1, 2024, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30...
In response to the 2024 Federal Budget, Community Food Centres Canada (CFCC) expresses concern over the budget's failure to tackle the pervasive issue of food insecurity in Canada. With 1 in 5 people in Canada living with food insecurity, the federal...